Wedbush Cuts Bicara Therapeutics Price Target to $24 From $33
Wedbush maintained its Outperform rating on Bicara Therapeutics.
Related stories
BNY Mellon Reports Third-Quarter 2026 Revenue of $5.68 Billion
Revenue rose 11.7% year over year to $5.68 billion. Net income attributable to common shareholders increased 20.1% to $1.61 billion, and diluted EPS rose 24.5% to $2.34.
M impact | EQUITY | Oct 30, 2026, 11:11 AM UTC
Exxon Mobil Q3 Adjusted Earnings Beat Estimates, Revenue Rises
Exxon Mobil reported Q3 adjusted earnings Friday; revenue rose.
M impact | EQUITY | Oct 30, 2026, 11:08 AM UTC
HSBC Upgrades GE Vernova to Buy, Raises Price Target to $1,100
HSBC raised its price target from $1,040 to $1,100, citing gas demand and a less risky outlook for the wind business.
H impact | EQUITY | Oct 30, 2026, 11:06 AM UTC
AstraZeneca Reports Third-Quarter Revenue of $16.21B
M impact | EQUITY | Oct 30, 2026, 11:05 AM UTC
BofA Securities Downgrades NMI Holdings to Neutral, Cuts Target to $44
BofA Securities lowered its price target from $51 to $44. The revised target implies 1.9% upside from the Oct. 29 close of $43.18.
M impact | EQUITY | Oct 30, 2026, 11:05 AM UTC
Citizens Financial Services Reports Unaudited Third-Quarter 2026 Results
M impact | EQUITY | Oct 30, 2026, 11:05 AM UTC